Archives
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
May 3rd, 2023 Cancer treatment in South Korea, CAR T-Cell therapyMay 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manufacturing process to express a synthetic rece.... Read More
Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
May 2nd, 2023 Blood cancer, Cancer, LymphomaMay 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score o.... Read More
Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
May 2nd, 2023 Blood cancer, CancerMay 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignancies who are scheduled to receive an umbilical.... Read More
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
May 2nd, 2023 Cancer, Urethral cancerMay 2023: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelia.... Read More
Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma
April 26th, 2023 Cancer, Cancer treatment in China, Cancer treatment in India, Cancer treatment in Israel, Cancer treatment in Japan, Cancer treatment in Malaysia, Cancer treatment in South Korea, cancer treatment in Thailand, Cancer treatment in Turkey, Merkel cell carcinomaApril 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell cancer (MCC). In PODIUM-201 (NCT03599713.... Read More
Tumor Infiltrating lymphocytes (TIL) Immunotherapy in India
April 7th, 2023 Cancer, Cancer treatment in India, ImmunotherapyApril 2023: Using the body's immune system to fight cancer cells is the goal of the promising cancer treatment method known as tumour infiltrating lymphocytes (TIL) immunotherapy. The process entails taking immune cells called TILs out of a pat.... Read More
Lesser known facts about esophageal cancer
April 5th, 2023 Esophageal cancerApril 2023: April month is observed as esophageal cancer awareness month. Esophageal cancer is a type of cancer that affects the esophagus, the muscular tube that connects the throat to the stomach. Here are some lesser-known facts about esopha.... Read More
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 24th, 2023 Breast Cancer, Cancer, Cancer treatment in China, Cancer treatment in India, Cancer treatment in Israel, DrugsMarch 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with early-stage, no.... Read More
Sam Neill, “Jurassic Park” actor, has been diagnosed with blood cancer
March 19th, 2023 Blood cancer, Cancer, CAR T-Cell therapyMarch 2023: The first chapter of Sam Neill's memoir would be a tremendous shock to someone who had no prior knowledge of it. It starts out funny enough: a great yarn about his daughter Elena being questioned about her father's job at school whe.... Read More
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
March 17th, 2023 Cancer, Cancer treatment in China, CAR T-Cell therapy, Ovarian CancerMarch 2023: Brief Summary: The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors CAR T-cell therapy for relapsed and refractory epithelial ovarian cancer. Detailed Description: Pri.... Read More
